Feeds

Friends and families deal with drug trial fallout

Victims 'screamed'

Secure remote control for conventional and virtual desktops

Details continue to emerge of the London drug test that put six volunteers in a critical condition.

Speaking to the Mirror, Dolores Flanagan, aunt of 21-year-old Ryan Wilson, one of the men that reacted badly to the drug, said: "The family are in pieces. He's in the hands of God now."

The Sun got hold of one of the more fortunate participants in the trial, who seems to have been given a placebo. Raste Khan said: "Some screamed out that their heads felt like they were going to explode."

Late this afternoon, authorities at Northwick Park Hospital in London said the condition of four of the men is showing signs of improvement. A statement said: "The other two men remain critical and it could be a while until they show significant change."

Student David O'Donnell, 19, was due to take part in the next stage of testing of the drug in April at a higher dose. A friend of his took part in the trial and is seriously ill. O'Donnel told the BBC: "I am very worried about him indeed, but I had a message from my friends to say they have managed to get in contact with him."

The distressed girlfriend of one of the men said yesterday that he looked like "the Elephant Man". Northwick Park intensive care clinical director Ganesh Suntharalingam tried to calm fears: "These patients sometimes need a lot of fluid, and one result of that is severe but temporary swelling. This is distressing for relatives to see, but it does go away on recovery and it has no long-term effects."

The experimental drug TGN1412 administered to the six was aimed at combatting immunological diseases - chronic conditions like rheumatoid arthritis, multiple sclerosis and leukaemia. German firm Tegenero had contracted American firm Parexel to carry out the first human trials for the new therapy in Britain.

TGN1412 is designed to target rogue T-cells which cause these illnesses. In the trial it triggered a massive inflammatory response in the healthy human volunteers, despite passing animal testing without problems.

TeGenero says it has apologised to the sick men's families.

A TeGenero statement says: "The drug was developed in accordance with all regulatory and clinical guidelines and standards."

Parexel works as a contractor running testing of many new drugs. It agreed that all guidelines had been followed. Its testing programmes draw in cash-strapped students with offers of easy money. Parexel's website trumpets: "Paid time to yourself."

It's unclear if there will be any kind of compensation pay out.

In an open letter to the British Medical Journal back in February, University of London Professor Desmond Laurence criticised the unclear arrangements for compensation when drug trials go wrong.

He said documents covering drug trials were not written in plain language and therefore did not meet the legal requirement of fairness and openness under consumer law. He observed: "The cost of compensation for non-negligent harm falls upon the injured patients themselves."®

Next gen security for virtualised datacentres

More from The Register

next story
Vulture 2 takes a battering in 100km/h test run
Still in one piece, but we're going to need MORE POWER
Boffins ID freakish spine-smothered prehistoric critter: The CLAW gave it away
Bizarre-looking creature actually related to velvet worms
TRIANGULAR orbits will help Rosetta to get up close with Comet 67P
Probe will be just 10km from Space Duck in October
CRR-CRRRK, beep, beep: Mars space truck backs out of slippery sand trap
Curiosity finds new drilling target after course correction
ANU boffins demo 'tractor beam' in water
The current state of the art, apparently
China to test recoverable moon orbiter
I'll have some rocks and a moon cheese pizza please, home delivery
What does a flashmob of 1,024 robots look like? Just like this
Sorry, Harvard, did you say kilobots or KILLER BOTS?
NASA's rock'n'roll shock: ROLLING STONE FOUND ON MARS
No sign of Ziggy Stardust and his band
Why your mum was WRONG about whiffy tattooed people
They're a future source of RENEWABLE ENERGY
prev story

Whitepapers

5 things you didn’t know about cloud backup
IT departments are embracing cloud backup, but there’s a lot you need to know before choosing a service provider. Learn all the critical things you need to know.
Implementing global e-invoicing with guaranteed legal certainty
Explaining the role local tax compliance plays in successful supply chain management and e-business and how leading global brands are addressing this.
Build a business case: developing custom apps
Learn how to maximize the value of custom applications by accelerating and simplifying their development.
Rethinking backup and recovery in the modern data center
Combining intelligence, operational analytics, and automation to enable efficient, data-driven IT organizations using the HP ABR approach.
Next gen security for virtualised datacentres
Legacy security solutions are inefficient due to the architectural differences between physical and virtual environments.